Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Blincyto Blinatumomab Withdrawn Jun 29, 2018
Blincyto Blinatumomab MRD+ ALL Resubmission Reimburse with clinical criteria and/or conditions Complete Jan 20, 2020 Oct 29, 2020
Blincyto Blinatumomab Acute Lymphoblastic Leukemia (pediatric) Reimburse with clinical criteria and/or conditions Complete Feb 24, 2017 Aug 23, 2017
Blincyto Blinatumomab Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete Aug 31, 2018 Apr 4, 2019
Blincyto (Resubmission) Blinatumomab Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete Feb 24, 2017 Aug 31, 2017
Bosulif Bosutinib Chronic Myeloid Leukemia Reimburse with clinical criteria and/or conditions Complete May 30, 2014 Apr 21, 2015
Bosulif (RFA) Bosutinib Chronic Myeloid Leukemia Complete Apr 8, 2019
Cabometyx Cabozantinib HCC Reimburse with clinical criteria and/or conditions Complete Oct 16, 2019 Apr 22, 2020
Cabometyx Cabozantinib Renal Cell Carcinoma (RCC) Reimburse with clinical criteria and/or conditions Complete Sep 17, 2018 Feb 20, 2019
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Reimburse with clinical criteria and/or conditions Complete Apr 7, 2020 Jan 8, 2021